This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk12: Ladies and gentlemen, thank you for standing by and welcome to the first quarter 2021 Zenon Pharmaceuticals Earnings Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press the star then the one key on your touchtone telephone. Please be advised that today's conference is being recorded. If you recall all your assistants, please press star then zero. I would now like to hand the conference over to your speaker host. Jody Rex, please go ahead.
spk03: Thank you. Good afternoon. Thank you for joining us on our call and webcast to discuss our first quarter 2021 financial and operating results. Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer, Ian Mortimer, Xenon's President and Chief Financial Officer, and Sherry Olin, Xenon's Vice President, Finance. As a reminder, this coming June, at the time of the company's annual meeting of shareholders, Simon will be transitioning to his new role as Executive Chair of Xenon's Board. At the same time, Ian will be appointed President and Chief Executive Officer, while Sherry will be appointed Chief Financial Officer. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the anticipated impact and timing of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations, the timing of and results from clinical trials and preclinical development activities of our proprietary and partnered product candidates, the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our proprietary and partnered product candidates, the anticipated timing of IND or IND equivalent submissions, and the initiation of future clinical trials for our proprietary products and those related to other partnered candidates. the efficacy of our clinical trial designs, our ability to successfully develop our proprietary development programs, the timing and results of our and our collaborators' interactions with regulators, the timing and anticipated enrollment in our clinical trials, the potential receipt of milestone payments and royalties from our collaborators, our expectation of having sufficient cash to fund operations into 2023, and the timing of potential publication or presentation of future clinical data. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statements. Today's press release summarizing Zenon's first quarter financial results and the accompanying quarterly report on Form 10Q will be made available under the investor section of our website at www.zenon-pharma.com and filed with the SEC and on CDAR. Now, I would like to turn the call over to Ian.
spk08: Thanks, Jody, and good afternoon. Thanks, everyone, for joining us. I hope everyone is healthy and well. We have made significant progress over this past quarter and I'm excited to provide an update today as we enter a period of important clinical data readouts over the coming quarters. I'll focus on our two proprietary KV7 programs, XEN 1101 and XEN 496. Later in the call, Simon will update you on our XEN 007 CAE program as well as partner programs with academic and industry collaborators followed by a financial update from Sherry. We'll then open the call up for your questions. So I'll begin with XCN 1101, which is a novel next-gen KV7 modulator being developed for the treatment of epilepsy and potentially other neurological disorders. We are very encouraged about the compelling product profile that is emerging for XCN 1101. In addition to my comments on XCN 1101, Simon will provide some commentary on our work examining XCN 1101 in indications outside of epilepsy. In the near term, Our focus is on the upcoming data readout from our Phase IIb XTOL study. As a reminder, XTOL is designed as a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy, safety, and tolerability of XCN1101 administered as adjunctive treatment in approximately 300 adult patients with focal epilepsy. The primary endpoint is the median percent change in monthly focal seizure frequency from baseline compared to the treatment period of active versus placebo. We believe that this is a well-powered and well-run study, which gives us confidence in the integrity of the key efficacy endpoints as captured by eDiary. I am pleased to report that we have now completed patient screening with the final patients now in the baseline period of the study. Patient randomization is expected to be complete in June, with top-line data anticipated by the end of the third quarter of this year. Given our current numbers already randomized and those last subjects in baseline, we expect we will randomize more than 300 subjects. This upcoming data readout represents a notable inflection point for Xenon and an opportunity to drive XEN 1101 forward into a late-stage pivotal program. Given this importance, I'd like to expand upon the unique properties and potential advantages associated with XCN 1101. First, some comments on the potential efficacy of XCN 1101. XCN 1101 is based on a previously proven KV mechanism of action with broad anti-seizure activity. We reported strong target engagement in our phase 1B transcranial magnetic stimulation study. Interestingly, from our interviews and research with KOLs and community healthcare providers, we understand that the efficacy of many anti-seizure medications is perceived to be roughly equivalent and that the other ease of use and tolerability attributes are important in prescribing decisions. Therefore, if we obtain efficacy measures that are statistically significant and within the range of other anti-seizure medications, there are a number of other positive attributes of XEN1101 that we believe could further differentiate it within the adult focal epilepsy market. We believe that XEN1101 has the potential to address some key ease of use considerations for physicians, and XEN1101's KV7 mechanism would represent the only drug in its class available on the market. From our discussions, we believe that this unique mechanism of action and currently apparent low DDI risk may be leveraged in a rational polypharmacy approach. We believe Exxon 1101's one pill, once daily dosing may be attractive to both physicians and patients with a forgiving PK profile that may provide coverage for missed doses. Additionally, no drug dose titration is envisaged, which compares favorably to the majority of other therapies used to treat adult focal seizures. Further, given that ASMs are generally perceived as having non-differential efficacy, the safety and tolerability profile is another key treatment driver. XEN-1101 was reported as safe and well-tolerated in a Phase I clinical trial. When taken as an evening dose, the drug CMAX is reached during sleeping hours, and thus patients may avoid some CMAX-related CNS AEs. Additionally, based on the lower than model dropout rates and high conversion to open label extension and extol, we have further reasons to believe that XCN1101 could have competitive safety tolerability properties. Digging in a little deeper into the potential mood benefits of XCN1101, we have strong scientific rationale to further explore major depressive disorder or MDD based on preclinical data and clinical work to date. that supports the use of KV7 modulators for the treatment of depression and anhedonia. If XEN1101 could present a mood benefit beyond its impact on seizures, this added positive effect would also be a key differentiator. And if XEN1101 has a good safety and tolerability profile without psychiatric AEs, this too could potentially encourage its use. On the whole, taking into account our conclusions from preclinical studies and clinical results to date, along with the market research exploring the current gaps in the adult focal epilepsy space, we believe XEN-1101 has a product profile that could be meaningfully differentiated from other anti-seizure medications. Turning now to XEN-496, which is a proprietary pediatric formulation of the active ingredient azogabine, that we're developing for the treatment of KCNQ2 developmental and epileptic encephalopathy, or KCNQ2-DEE, a rare severe pediatric neurodevelopmental disorder. Now in phase three development, XEN496 represents our most advanced program in the clinic, and we have received fast track designation and orphan drug designation in the U.S., as well as orphaned medicinal product designation from the European Commission. Our Phase III EPIC clinical trial is evaluating the efficacy, safety, and tolerability of XCN496 administered as adjunctive treatment in approximately 40 pediatric patients aged one month to less than six years with KCNQ2-DEE. Designed as a randomized, double-blind, placebo-controlled parallel group, multicenter clinical trial enrollment is underway. Our team continues to collaborate with KOLs, physicians, and patient advocacy groups to identify potential patients. We recently hosted a webinar in partnership with the KCNQ2 Cure Alliance Foundation, which featured Dr. John Millichap, our principal investigator of the EPIC study, who outlined study details and answered questions about the clinical trial from the families of the KCNQ2 DEA patients. Based on its KV7 mechanism of action, as well as published physician case studies, we believe that XEN496 has the potential to address an important unmet medical need for these young patients. And we look forward to keeping you updated on the progress of the EPIC study. At this point, I'll ask Simon to provide an update on our work with academic collaborators and industry partners, including the investigator-led studies with both XEN007 and XEN1101. Simon?
spk05: Thank you, Ian. This is an exciting time for Xenon as our partnered and proprietary programs continue to make great progress. As Ian mentioned, we're exploring other neurological indications for XEN-1101 outside of adult focal epilepsy. I wanted to highlight for you today the recent Costi et al. article published in the American Journal of Psychiatry examining the use of izogabine on the reward circuit activity and clinical symptoms of depression in a randomized clinical trial. Izogavine, compared with placebo, was associated with a significant improvement in depression, as measured by the Montgomery-Asperg Depression Rating, or MADRAS, scale, and associated with a significant improvement in hedonic capacity, as measured by the Snaith-Hamilton Pleasure, or SHAP, scale. We believe these new data provide further validation of the great potential of the KV7 mechanism to differentiate from other anti-seizure medicines available. in patients with epilepsy and the comorbidity of depression, or a standalone to treat MDD. We recently announced a collaboration with the Icahn School of Medicine at Mount Sinai in New York, and we expect that an investigator-sponsored Phase II proof-of-concept randomized parallel-arm placebo-controlled clinical trial examining XEN1101 as a treatment for MDD and anhedonia, as measured by specific functional and clinical endpoints, will be initiated in the coming months. In parallel, we're planning a company-sponsored study in MDD, focusing on clinical endpoints. Both of these planned MDD studies are supported by promising preclinical data with XEN1101, as well as clinical data generated from open-label and randomized placebo-controlled studies that explored targeting the KB7 mechanism using izogabine as a potential treatment for MDD. We're excited about this focus on the potential of the KV7 mechanism and the related promise for XEN-1101 to be the only in-class drug in adult focal epilepsy with the potential for broader opportunities in other neurological disorders given XEN-1101's unique pharmaceutical attributes. Turning now to XEN-007, which is a CNS-acting CAV2.1 and T-type calcium channel modulator, being studied in treatment-resistant childhood absence epilepsy, or CAE, in a physician-led Phase II proof-of-concept study. At the virtual AES 2020 meeting, we presented promising interim data from a small number of patients that showed three CAE subjects exhibiting a significant reduction in seizures as measured by seizure diary and confirmed by EEG. And while this is a small data set, We believe we are seeing drug activity and seizure reduction that is supportive of a broader development plan for XEN007. As we have stated previously, the COVID-19 pandemic has impacted recruitment in this investigator-led study. However, we are adding other sites, and we expect to be able to provide results from a larger data set in the second half of 2021. I'm pleased that our industry-partnered programs also continue to advance and progress. Our collaborator, Neurocrine Biosciences, continues to guide the initiation of two Phase II clinical trials this year to evaluate the use of NBI 921352, which used to be called XEN901, in both pediatric and adult indications with planned studies in patients with SCN8A, developmental and epileptic encephalopathy, or SCN8A-DEE, and in focal epilepsy, respectively. In addition, we continue to make good progress on the advancement of earlier stage molecules within our ongoing discovery-based collaboration with Neurocrime. We're also excited to report that our partner, Flexion Therapeutics, recently announced treatment of the first patient in a Phase 1B proof-of-concept trial, evaluating the safety and tolerability of FX301 administered as a single-dose popliteal fossa block in patients undergoing bunionectomy. Flexion's FX301 consists of a xenon-developed molecule, previously known as XEN402, which has been formulated for extended release from a thermosensitive hydrogel. Flexion has guided that it anticipates data from the Phase 1B trial of FX301 in late 2021. I'll now ask Sherry to recap our financial position. Sherry?
spk02: Thanks, Simon. We are in a solid financial position today and I believe we are well situated to support Zenon's business objectives and the advancement of our clinical development programs. Today I will focus on some highlights from this quarter's financial statements and would refer you to our news release and 10Q report for further details. Following up on Simon's comments on the progress made by our partner Flexion, this quarter we recognized $3 million in milestone revenue and we are eligible to receive additional milestones and royalties in the future. This past quarter, we also closed an oversubscribed $115 million public offering, with strong support from both existing and new high-quality institutional investors. Cash and cash equivalents and marketable securities as of March 31, 2021, were $274.7 million, compared to $177 million as of December 31, 2020, based on current assumptions which include fully supporting the planned clinical development of the XCN 1101 EXTEL trial and MDD proof of concept study, the XCN 496 EPIC study, the XCN 007 physician-led proof of concept study, As well as funding our pre-clinical and discovery activities, we anticipate having sufficient cash to fund operations into 2023, excluding any revenue generated from existing partnerships or potential new partnering arrangements. We plan to revisit our cash runway guidance post-EXTOL data with increased visibility on our spend in 2022 and beyond. With our strongest balance sheet to date, we continue to have a lot of flexibility as we manage our business and continue to advance our product candidates. As of March 31, 2021, there were approximately 41 million common shares outstanding, 1.1 million pre-funded warrants, and 1 million Series 1 preferred shares outstanding. I would refer you to today's press release and our 10-Q filing for other specific details from this quarter's financial statements. At this point, I will turn the call back to Ian, who will summarize the key milestone events We are anticipating for the remainder of this year. Ian?
spk08: Thanks, Sherry. Looking ahead, our key corporate objectives include the continued advancement of our EPIC Phase III clinical trial in patients with KCNQ2-DEE, a development decision and results from a larger data set in the second half of the year from the physician-led XCN007 proof-of-concept study in CAE, continued support for our partner program with Nurocrine Biosciences, including the anticipated initiation of two Phase II clinical trials with MBI 921352 in 2021, results from Flexion's FX301 Phase 1B trial anticipated in late 2021, anticipated initiation of an investigator-led Phase II proof-of-concept study, as well as the ongoing planning for a company-sponsored clinical trial examining XCN1101 in MDD, and importantly, Within our XCN 1101 Phase 2B XTOL clinical trial, we expect patient randomization to be complete in June, with top-line data anticipated by the end of the third quarter this year. In summary, we are incredibly proud of the breadth and depth of our neurology pipeline. There is an immense amount of momentum in both our proprietary and partner programs. For the first time in Xenon's history, we could have up to eight clinical trials underway with five different molecules led by us, our corporate partners, and academic collaborators in 2021. Before we open the call up for your questions, Simon has a couple of concluding remarks. Simon?
spk05: Thank you, Ian. So this is my last quarterly call as Xenon's CEO. As you know, I'm handing that baton over to Ian, who has worked alongside me for the past seven years. I leave this role with great anticipation and optimism, in part driven by the strength of our current pipeline, in part driven by the exciting data readouts ahead of us, and in part driven by the strong leadership at Xenon that will continue to work tirelessly for you, our shareholders, as well as the patient communities we serve. It's been a privilege to serve such a talented executive team and to work alongside such wonderful colleagues. This has been an incredible honor and a mission for me, a journey I'll always treasure. As you know, I'll be working in a different capacity as Executive Board Chair, and in that capacity, I look forward to continuing to support Xenon and to interacting with all of you. I wanted to thank you all for the faith that you have shown in me and the faith you have shown in Xenon. I firmly believe that our best is yet to come. I'll now ask the operator to open the line for any questions. Operator?
spk12: Thank you. Ladies and gentlemen, to ask a question, you will need to press the start and the 1 key on your touch-tone telephone. To withdraw your question, press the pound key. In fairness to all participants, please limit yourself to one question and one follow-up. Now, first question coming from the line of Paul Matisse with Stifel, your line is open.
spk08: Paul, can you hear us?
spk05: Operator, perhaps we go to the next question just while Paul tries to solve the technical issue. Operator?
spk12: And our next question, coming from the line of Laura Schicker with Web of Securities. Your line is open.
spk04: Best wishes, Simon, and congratulations to Ian and Sherry again. I guess I have one question on 1101, so obviously exciting to hear that the X toll readout is coming up in the third quarter. Beyond the primary endpoint, I'm wondering if you could talk about the communication strategy around some of the perhaps non-seizure related assessments, quality of life measures, and then I just have one follow-up for you.
spk08: Yeah, thanks, Laura. Maybe I'll answer that by providing a little bit of background and color. So as we mentioned, we'll have top-line data by the end of Q3. That'll be by way of a press release. We'll have key endpoints. We haven't mapped out everything that'll be in that first press release. It will come after we unblind data, just how much of the data analysis we can do, balancing getting out that top-line data in as quick a manner as we can. Key efficacy endpoints, primary and secondary, for sure, as you know, the primary we talked about on today's call. Key secondary endpoints focus on a lot of the responder analyses, and we'll have some data on those. We'll definitely comment on safety and tolerability and some other metrics within the study. And as you mentioned, we do have some additional endpoints around quality of life. how much of that full data analysis will be completed and ready for the top line data. We don't know right today, so we will be ready to talk about that at the next quarter in advance of data. And then as a standard, we'll have more detailed analyses upcoming at scientific meetings. We may be able to get just under the wire for a late breaker at AES this year, which would be excellent. And then, obviously, we have AAN next spring, our conferences that we're looking forward to presenting additional analyses.
spk04: That's great, Ian. Thank you. And then maybe one follow-up on the commercial market in the focal epilepsy setting. It's been about a year since COPRI has been on the market. You know, obviously, there will be some additional studies to conduct with 1101 if successful here, but I'm just curious if you could talk about any learnings or takeaways that you could take from Sinovamed's year on the market. Thanks very much.
spk05: Yeah, Simon, I'll make a comment. I'll hand over to Ian for some additional color. Yeah, look, I mean, just as conjecture, I'm not going to give you a perspective from a detailed analytical review. But, you know, look, Sinovamed certainly has shown at its final dose to have a good effect size in a proportion of patients with this condition. It is a significant titration required to get there, three to four months of dose titration. And so I think what needs to still play out in terms of the real world usage of the drug is really how well that can be integrated into a refractory focal epilepsy patient population. These are patients that are having regular seizures and having to wait, you know, this amount of time to get drug to a final concentration required for maximal effect, I think we'll have some limitations. And it's one of the key differentiators with 1101. We don't need to titrate the drug, and we appear to reach a maximal steady state exposure at around plus or minus two to three weeks with no long-term accumulation. So I think that's a really significant differentiation. Of course, We've not seen any of the hyper-eosinophilic syndrome that was observed in studies with higher-dose excopri in our studies to date, and we don't have any reason to believe we will. But, of course, the dose titration differential, I think, is going to be very, very important. Ian referred to the ease of use and once-a-day use. I think both of those are going to be very, very important differentiating concepts. And I think you can look to a drug like Vimpat or Lacosamide, which is far less effective in terms of median seizure frequency reduction, 35 to high 30% in median seizure versus plus or minus 50 with Excopri, yet is selling about $1.5 to $2 billion a year largely because of its ease of use in this indication. So I think that's some of my own personal color.
spk08: Ian? Yeah, maybe just a couple of comments. So we don't have perfect information on your specific question on how the launch has gone for XCOPRI, but our understanding is that it's gone reasonably well. And obviously this is a large market opportunity with still significant unmet need where There is absolutely room for a number of branded drugs to do well. You know, I think Simon walked through a lot of the differentiating points. The other thing that I would mention that we didn't cover on this call but we have presented recently is that we've generated some really nice preclinical data of 1101 in combination with Sinovimate. Obviously, different mechanisms of action. And when you dose these drugs together, you can get quite significant efficacy in the in vivo models that we've run. So, you know, we look forward to having 1101 as another drug available for physicians and their patients.
spk04: Thanks very much, guys.
spk12: The next question coming from the line up.
spk07: Hey, thank you. Can you guys hear me? We can. We now can, yeah. All right. Awesome. Thank you. Sorry about that. Well, first off, congrats, Simon, and congrats, Ian, on your new role. Always appreciate the dialogue you've had. I wanted to ask a question on the MDD plans and then also on the O7 plans. On MDD, what's your kind of current thinking on MDD? when you're going to engage the FDA, what the next study could look like, and how are you thinking about dosing an MDD? Is it same as epilepsy, or might you try to go a little bit lower due to just tolerability dynamics? And then for 07, I guess similar question, just plans to engage the FDA. Would you do that after this initial investigator data, or would you start before, and how do you think about next steps? Thank you.
spk08: Sure. I'll start, Paul, and then Simon can add. So on the MDD side, we don't believe we need any upfront engagement with the agency to move ahead with a company-sponsored MDD. We're not looking for any specific feedback. Obviously, we'd need to file a protocol and get up and running, but there's not specific feedback that we're looking for. I think with the Izaga being experienced from Dr. Murrow and his group at Sinai, and other trials that have been run in MDD, we have a pretty good protocol synopsis already that we're working on. We are looking to use, we haven't finalized the dose, but we'd be looking to use a dose that we're currently using in the epilepsy study where we just have a lot of experience. That said, from just an order of events perspective, before we start the MDD study, the Sinai study will start before, The Sinai study will start, and then we'll have the XTOL data. So we will have some information on unblinded XTOL data of 1101 before we initiate the company-sponsored MDD study. So that is another data point that we can take into consideration as we refine our thinking. On 007, our plans are really in parallel. So this year is both to expand the data set from from those few number of patients where we saw some intriguing data at AES last year. So that's the goal for the second half of the year. And then in parallel, we do expect to have some regulatory interaction to talk about next steps in the development. And obviously, our planning if the data continues to support it in CAE is to run company-sponsored development Exactly what that looks like is really what we're doing in terms of our development planning right now, and then we expect to have that regulatory interaction later this year.
spk05: Paul and Simon, the only thing I'd add is, you know, just going back to the MDD, you know, key distinctions, I guess, from the Zogabine study and also from the current study Dr. Murrows will run with 1101 is In those studies, functional MRI was the primary endpoint with clinical secondaries. You know, we're much more interested in our sponsored study as clinical primaries. I think the other unknown at this point, which we'll define still, is going to be, you know, the interplay with anhedonia in our sponsored study. So, as you know, the isogabine study was done in MDD and anhedonic patients and will similarly be tested in with Dr. Murrow's 1101 trial. We're currently sort of looking through that to decide whether, you know, we'll have a purer MDD patient population meeting thresholds of severity in terms of inclusion. I think that's the only additional comment I'd make.
spk07: Great. Thank you, Simon. Appreciate it.
spk12: Okay. Next question. Our next question in queue coming from the line of Mark Goodman with SBB Learing. Your line is open.
spk11: Yes, hi. Simon, in the past, you kind of hinted at work that's going on behind the scenes. You're talking about disclosing some of that work soon. I was just wondering, are we getting closer? What's going on behind the scenes? Maybe you could just give us a little hint. Thanks.
spk05: I mean, you're probably referring to what's our non-clinical programs, Mark. Yeah, look, we have some very exciting work underway, some of which we've talked about in the past. We do have, you know, a KV7 program that obviously is looking at next generation molecules, which has made outstanding progress. You know, we have an NAV 1.1 program targeting Dravet and potentially other indications, which has also made some very exciting progress. And then we have a few other programs in addition, which we aren't yet ready to talk about, but certainly over the coming months I expect we'll be talking a bit more. So, you know, this is This is really just a stage of the programs, Mark. We'll make disclosures when we think they've really moved to a material stage, and up until then, we'll keep the programs under wraps. Those are just two of the programs we have referenced in the past. There are others, but that's about what we'll cover for now.
spk11: And then just one quick follow-up from a previous question or two about 007. I guess, how many patients do we have right now that's already been enrolled, and how many is the goal for this year?
spk08: Hey, Mark at CN. So we haven't, just like any other clinical trial that we run, we don't give updates kind of quarter to quarter on where we are in enrollment, only when we hit kind of key inflection points. You know, our goal is, we've always said that You know, the first three patients, the data looked really intriguing, and if we could get to, you know, kind of 10-plus patients and then continue to enroll patients and study in that population, as we get more and more subjects in that study, it just gives us more confidence in that opportunity and that indication. So the goal was to increase from the handful into double digits and then grow from there.
spk11: Okay, thanks.
spk12: Our next question coming from the line of Tim Lugo with William Blair. Your line is open.
spk09: Thanks for taking the question and congratulations to the team as well on their new roles. For going back to 1101 and MDD, I believe the Mount Sinai study is going to take relatively long to enroll given the NIH's role in the study as well. Can you just talk about maybe the company-sponsored study and how that might – I assume that should be faster to conduct, especially if you're using clinical endpoints versus the fMRI?
spk08: Yeah, that's right, Tim. I think the way we think about it – and you're probably referring to the clinicaltrials.gov posting from Sinai that that study may take a few years. You know, I think – Unknown right now and hopefully as that study gets up and running We can get a little bit more granularity on when we may see top-line data But our expectation is that the Sinai study will start first Our study would follow but our study would likely read out first and really for the reasons that you talked about primarily Sinai is going to be at two centers. We would go to more than two and And with our control with the CRO, it would likely enroll more aggressively than the Mount Sinai study.
spk09: Okay, thanks for that. And I guess given the low DDI risk in epilepsy, have you explored kind of adequate DDI information for similar classes used in MDD as well? Or was that all work done kind of concurrently in the epilepsy DDI information?
spk08: So we've done, you know, where we are in development for 1101, we haven't completed all of the DDI work that would be required. We've done, you know, standard DDI work regardless of therapeutic indication. So a lot of the in vitro work and other profiling that we believe overall it's going to have low DDI risk. The Mount Sinai study, this is dosed as a single agent. We haven't made a final decision on our MDD study on whether they'll be con meds or not. But overall, the profile 1101, we believe it has low DDI risk. We're also initiating more detailed PK PD modeling with the initial data set being the clinical data that we've generated to date in phase one to start building that model. But once we have all of the phase 2 EXTOL data in hand, then our PK PD modeling can become more robust and we can see if there's any differential exposure from 1101 or other con meds depending. As you know, all of the patients in EXTOL will be on those background therapies and so we'll be able to have a better understanding of any DDI as we generate more data and do more modeling.
spk09: Great. Thank you for the call.
spk12: Our next question coming from the line of Andrew Sywood. Jeffrey, your line is open.
spk00: Hi, guys. Thanks, and good afternoon. Big congrats on the progress as well. For the XTOL study, very nice to see that it's wrapping up soon. So can you talk about what you would construe as positive safety data? I mean, presumably you'll show AEs in the top line, but will you, for example, share biomarker data or other measurements like eye exams, chromateria, and so forth? Can you just talk a little bit about that?
spk05: Yeah, look, as Ian said, Andrew, we haven't, you know, we haven't nailed exactly what's going to be disclosed in the top line yet. So, of course, sort of high-level safety tolerability will be... You know, I think we need to think this through carefully. We obviously recognize there are certain safety tolerability data sets which are going to be very, very relevant. We understand that. Some of that, I think, will, you know, be particularly important over time. So eye measurements are being done. You know, obviously urine is being looked at. Urinary hesitancy and or... Retention, of course, is being captured if any has occurred. So we will have that data. I think Ian made the point earlier, which I think is always the point in top line is balancing the speed to present with that material information in hand with the amount of data analysis one needs to do. And so, you know, typically we would do these staged releases driven by at least having this top line material data in hand, press release that, as Ian said, with a press release, and then follow up with a number of what we know are important analytics, which will, you know, come between now, then, and AES as your likely time point. So hard to pinpoint exactly at this point what's going to be in that first press release, Andrew, but, you know, we'll we'll come up with a plan as when Ian said, I think before data, after the second quarter, we'll probably be in a position to upload and should I say to download on what is exactly gonna be presented.
spk00: That's very clear. And my second question is actually back at Ascent, back at the Ascent conference, I believe one of your team members affirmed that a handful of patients had completed the open label phase None of them had seen any safety issues. If that's true, I'm wondering if there have been more patients who have completed the open-label phase and the safety profile still looks pretty pristine as you had expected. Thanks.
spk08: Yeah, I mean, I won't make any specific comments on safety. Yeah, I will confirm. So the way the study on the open-label extension, the way the study was designed Initially, as we know, it's an eight-week double-blind with the opportunity for every subject regardless of dose group or placebo to go on to open-label extension. And we've said we've had a very high conversion rate into OLE. OLE is at a single dose, which is 20 milligrams. And that OLE was initially designed as 12 months, which is quite standard. We had, starting at the end of last year and into the early part of this year, as patients were rolling off of 12 months, we had questions and asks from physicians and steering committee members for a continuation of the open label extension, and we did that, and we extended OLE out to three years, and we've gone through a number of key regulatory filings to extend that. And I think where that, maybe to link back to your earlier question, I think where some of that long-term safety data is gonna be important is your question around some of those safety events that showed up with azogabine after cumulative dosing over a longer period of time. So the more data that we can collect for patients going out more than a year or multiple years, when we talk about pigmentation risk, To be clear, the position from us at the company is we don't believe 1101 has any pigmentation risk, but the more data that we can generate and release over time from open label extension is going to be important for a number of our constituents.
spk00: Great. Thanks for the caller.
spk12: And as a reminder, ladies and gentlemen, to ask a question, please press star 1 and please limit yourself to one question and one follow-up. Our next question coming from the line of Trish Valencia with Needham. Your line is open.
spk01: Hi, good afternoon. A couple questions for me. The first one on 1101, more specifically the MVD program. Just wanted to clarify something. You plan on initiating the program company-sponsored study before you get results from the physician study. And at this point, maybe I missed this and you prepared comments, but this is going to be open-label or placebo-controlled and dose-ranging. And then secondly, on the 496 EPIC trial, I think it's too early to give an enrollment update here, but maybe just give us an idea of how many sites are up and running and maybe... you know, with COVID restrictions, has that been a serious impediment to enrollment and should we expect a significant improvement once restrictions are lifted?
spk08: Thanks. Thanks, Serge. So, on the MDD question, so from an order of events, Yes, we expect the Sinai study is ready to be up. That study will start in the near term, so that one's ready to go. And then, yes, our current plan is to initiate a company-sponsored MDD study in advance of that physician-sponsored Mount Sinai readout. And the commentary we made in Q&A is that our expectation is although we can't predict with certainty today, but our expectation is that we'd have a readout of our study likely before the Sinai readout would be the likely order of events. You also had a question just on that trial design. We have a protocol synopsis. We're still in the planning stages of that study, but we would expect it to be a randomized study with placebo control. Maybe not dose range finding. We wanted to answer a number of questions in the EXTEL study around around dose, dose response, minimum effective dose, whereas likely in a proof-of-concept study in MDD, we would choose a dose in a placebo-controlled study. Moving to Epic, so the studies up and running, so this is XCN496, the Phase III program, and we have kind of what we've said in the past, and we don't get kind of granular on specific site numbers. But we expected it starting in the U.S. that really for the first few quarters of this year is when we were looking to get a number of sites up and running in the U.S. And then other jurisdictions outside of the U.S. would come online as the year progresses. So we're still on track for that. You know, I would say there's probably been some COVID impact. Um, you know, we do hear from sites that, uh, some of them have been, um, and that's probably lessening over time. Um, but, uh, they have been focused on either COVID clinical trials or, or sites that have just been busy, um, dealing with, uh, with the pandemic and dealing with COVID patients. So it's likely had some impact. It's always difficult to know exactly how much, um, but that's some of the feedback we've received. And then we've also mentioned as we get a couple of quarters into enrollment, that's when we'll be in a position where we'll feel comfortable trying to give some top line guidance on when we should see data from that study.
spk12: The next question coming from the line of Yatin Suneha with Guggenheim, your line is open.
spk10: Hey, guys. Thanks. This is Eddie on . So, just a high-level question on 1101. You know, how should we think about the potential efficacy coming next quarter in comparison to the old izogabine data? Do you need to show an enhanced efficacy profile over those older data, or is it really just a story about safety and dosing regimens? How should we think about those top-line data? Thanks.
spk08: Yes. So, Eddie, that's a good question. It's a question we often get. And we did design the statistical analysis plan and the powering for the study, taking into consideration the azogabine data. We know azogabine, same mechanism. The data that azogabine generated over a decade ago in adult focal epilepsy was statistically significant and was impressive. And so that was data that we've looked at and thought about as we've put in our assumptions into the modeling and the powering calculations. We've taken that into consideration. That said, you know, azogabine or potiga is no longer commercially available. It's not on the market. This isn't an active comparator. You know, and, you know, the treatment and the drugs that are available for these patients are different today than when azogabine was trialed. And so overall, you know, although I think that that's a backdrop that we think about, I don't think we need to necessarily compare to the azogabine data. We want to compare to where 1101 is going to fit currently in the anti-seizure market, both from an efficacy point of view, but importantly, as we talked about a lot on today's call, and we've done a significant amount of market research, is on the safety and tolerability profile and the ease of use attributes.
spk10: Gotcha, thanks. And then just really quickly on an AE profile, in the phase one you did show some mild cognitive effects. I'm just wondering if that's something that you think could be exacerbated in a larger study that we could potentially be concerned about. Thanks.
spk05: I'll take that, Simon, Eddie. Yeah, look, any phase one study with a CNS-acting drug in volunteers is likely to exaggerate the tolerability of of the drug, when you go to a community-based study in patients or an outpatient-based study, it's generally very, very different. These are patients that are used to taking or more used to taking anti-seizure meds. Remember, these individuals in our trial have been on many but are on one to three additional meds at the time of inclusion. So they're quite used to the tolerability. And we have also, as you probably recall, designed the study such that with dosing in the evening, which was different from our Phase I setting, which where the dosing was in the morning. But dosing in the evening in this trial, as Ian mentioned in his notes earlier, we should see C-max during sleeping hours. And that was specifically designed, given the PK of the drug, to allow for any of the more significant CNS tolerability issues to hopefully be slept through. And so we don't expect the AE profile to be the same as phase one. I will just say and reiterate that actually the phase one safety was relative to other drugs actually good and relative to isogabine was excellent. I mean we have Almost all were mild and were reversible and clearly a dose dependency with the aggregation of AEs at the 25-meg dose. Remember our, you know, but this study is dosed at night and in a patient population, so our population is quite distinct and we expect to see much improved tolerability. I think Ian mentioned earlier the very low dropout rates and the very high conversion to OLE would suggest that would suggest that at least the patients are tolerating a drug to a degree where they stay in the study and move into the open label where they and the investigators know they're getting the active drug.
spk10: Thank you. And then just one final one. Is there any possibility that this phase two could be potentially pivotal? Is that being considered? And then if it's successful, do you have a baseline assumption on how many other trials you'd need to get approval?
spk05: Yeah, that's a good question. We don't know because it's going to require an FDA discussion, but certainly if the study is very significant, remember it's a one-sided Phase II trial, so we'd have to essentially double the effect size in the terms of the p-value for this to potentially be deemed significant at a two-sided, which will be a requirement for this to be deemed registration. But assuming we were to see that, so in other words, a p less than 0.025 rather than less than 0.05, we would certainly engage the FDA on that discussion. And then, of course, the obvious discussion is do we just require one additional, for the U.S. at least, one additional phase three trial. For Europe, it's almost certain one would require two distinct studies, 12 weeks dosing designed as two-sided. But for the U.S., it is possible. that this could be deemed a registration, or should we say one of two registration trials. Remember, we still have to have a certain number of subjects in a safety database, and that number's around 1,500, but they don't all have to come from efficacy trials. They can come from clin-pharm studies, open-label studies, single-dose studies, et cetera. So we're going through that, Eddie, right now, but our goal would be to engage the FDA on that exact discussion if we see a highly statistically significant effect.
spk10: Thank you, and congrats, Simon. Thank you.
spk12: Our next question coming from the lineup, Antonio Poravino with Bloomberg. Your line is open.
spk13: Hi. Thanks for taking my question. I just have one, which was kind of related to a question asked earlier, but maybe another way of asking it. I know that your EXTEL trial is powered to show a 15% delta between placebo and active. So I'm just wondering if you just reached this threshold, do you believe this is competitive commercially from an efficacy perspective?
spk08: Ian, do you want to go? Yeah, I mean, that's a difficult question. question to answer because I think in all of these things, any prescribing decision is based on totality, right? It's not just based on a single data point. And it's interesting, when you talk to a lot of the community-based prescribers, I'm not sure that they can rattle off the clinical trial efficacy data like we can, right? So they're really thinking about the experience they've had with a drug, how their individual patients have done on that drug, what the and the prescribing decision that they're making. So I would never want to think about one single data point as being a driver of the ultimate commercial success for 1101. I would also say, yes, you know, the statistical, it's a well-powered study from a statistical perspective to show, it's a linear trend test to show a dose response and separation, and if you look at, you're correct, at the placebo versus the high dose of 25 milligrams, the modeling is a 15% differential. Obviously, that, you know, a bunch of other things go into that model at the end of the day in terms of the standard deviation and other things that would provide the p-value at the end of the day. So, you know, the way we think about it is if we're in that range, of that 30 to 40% median reduction, we need to be statistically significant, then we believe we're absolutely comparable to what the market is for efficacy and anti-seizure medications. And then when you start thinking about some of the other attributes, which are really a massive driver of how decisions are made, 1101, as you line it up against the other drugs both generic and branded drugs in adult focal epilepsy, that's where 1101 lines up really well. And I won't list those off right now, but we have gone through those in our prepared remarks where we believe both on an ease of use and safety and tolerability. So far, 1101 looks very strong.
spk12: Great. Our next question coming from the lineup, David Longwood, SMBC, your line is open.
spk06: Hi, thanks for the update and putting my questions in. So I just had a couple quick ones. With 1101, I know the inclusion criteria, you know, for the Phase IIb study allows one to three, you know, concomitant or background ADDs. So I was just wondering if you had a sense of how many patients are actually on only one background therapy, and in the real-world setting, do you think that you'd be able to pick up some patients in second-line usage, or would it mostly be third line plus that you expect?
spk08: Thanks, David. Good questions. We don't have, neither Simon nor I are in the details of exactly what the patient demographics look like in the current study. We purposely kind of stay away from that. So I don't know the answer today of your question on how many are on one, two, or three background meds in the study. Obviously, we'll be able to disclose that data once the trial is complete. When we think about the prescribing decisions, I mean, why don't we just spend a quick minute walking through them because we've done a lot of this work recently. So generally, yes, at first line, many of these, so first line meaning newly diagnosed patients, they are going to be on a generic drug. At second line, you're going to, you often see branded Keppra show up. And again, not every patient is the same and not every physician prescribing habits are the same, but you often see branded Keppra show up or other generics. And at that point, still we see a percentage of patients, you know, often it's quoted in the 30 to 40% range that are still not well controlled. And that's when physicians are starting to think about rational polypharmacy. That's where Vimpat often shows up as the first branded agent. And I think, you know, we believe that's where 1101, based on its attributes, also has the opportunity to play a role based on it's going to be the only in-class drug at launch with a KV mechanism, so it'll be a novel mechanism. and some of the other ease of use attributes that we've seen and obviously once we have the safety and tolerability and efficacy data in hand. But that's generally as we think about the progression of a patient and potentially where 1101 could fit in there or as additional agents are added to treat these patients.
spk06: Got it. Thanks for providing that's really helpful. And then just my question was on 007. I know the active ingredient is flunarazine, and there's been some experience, you know, commercially with that molecule. So it's just trying to get a better sense of, you know, what has the experience historically been with 007, you know, or flunarazine in terms of safety, tolerability, and, you know, efficacy and such. Sure.
spk05: Yeah, thanks. So it's approved on label outside of the U.S. in a number of countries, European, South American, and others, for chronic migraine prevention and vertigo. It's a CNS acting primarily calcium channel modulator, but it has some other effects. One of the actual very interesting features of the drug, which was compelling for us, is not only had there been some non-clinical data supportive of the use in CAE, But actually the tolerability of the drug, particularly in the pediatric population, is actually very, very good. So there are some side effects known with flunarazine, particularly in an elderly population. Depression and pyramidal or extrapyramidal features can be observed, again, at low frequency, but in the elderly population. I'd say the only AE outside of that population that one would need to consider is some weight gain. It's not that significant, but it is there in some subjects. But interestingly, in the pediatric population, this drug is very, very well tolerated, which is actually very important because often drugs used in kids for their seizure control, independent of type of seizure, this could be focal, this could be generalized, this could be absence, these are often drugs that impair the scholastic ability of these kids. They have cognitive impairment and kids feel sleepy. And so this is a drug which appears to be mostly devoid of those, certainly relative to the gold standard drugs in this indication being valproate and ethosuxamide. This would be a very good alternative from a CNS perspective. So it's actually one of the reasons David, we wanted to move this product forward in this population, you know, was because of the predicted excellent safety tolerability that's now been shown in tens and tens and tens of thousands of users of flunarazine around the world. Okay. Yeah. You said another way, if the drug fails, I don't think it's for safety tolerability. That would be my guess in this population. I think we don't, obviously, we don't know the final efficacy, albeit it looks very good in a small subset, but safety tolerability is well understood. Okay.
spk12: I'm not showing any further questions at this time. I would now like to turn the conference back over to Jody Rex for any closing remarks.
spk03: Thank you. On behalf of the Xenon leadership team, we look forward to updating you on our progress over the coming months. Operator, we will now end the call.
spk12: Ladies and gentlemen, that's the conference for today. Thank you for your participation. You may now disconnect.
Disclaimer